Adicet Bio (ACET) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.57, -11.09% vs the prior close of $5.14.
- Volume 188.44K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ACET slides 11.1% to $4.57, a 52-week low. Closed at $4.57, -11.09% vs the prior close of $5.14. Day range $4.57–$5.14, opened at $5.14.
ACET daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ACET slides 11.1% to $4.57, a 52-week low
- Closed at $4.57, -11.09% vs the prior close of $5.14. Day range $4.57–$5.14, opened at $5.14.
- Volume was 188.44K shares, 0.9x its 50-day average of 209.26K.
- Price is -43.3% vs its 50-day average ($8.06) and -42.2% vs its 200-day average ($7.90).
- 52-week range $4.57–$17.04; today's close sits at 0% of that range, 73.2% below the 52-week high.
Oct 15, 2026 — ACET jumps 5.1% to $5.14
- Closed at $5.14, +5.11% vs the prior close of $4.89. Day range $4.88–$5.17, opened at $4.90.
- Volume was 155.10K shares, 0.7x its 50-day average of 207.02K.
- Price is -36.7% vs its 50-day average ($8.12) and -35.1% vs its 200-day average ($7.92).
- 52-week range $4.80–$17.04; today's close sits at 3% of that range, 69.8% below the 52-week high.
Oct 14, 2026 — ACET slides 4.3% to $4.89, a 52-week low, 10 down days in a row
- Closed at $4.89, -4.31% vs the prior close of $5.11. Day range $4.80–$5.27, opened at $5.10.
- Volume was 357.80K shares, 1.8x its 50-day average of 201.78K.
- Price is -40.4% vs its 50-day average ($8.20) and -38.3% vs its 200-day average ($7.93).
- 52-week range $4.80–$17.04; today's close sits at 1% of that range, 71.3% below the 52-week high.
- That makes 10 straight losses.
Oct 13, 2026 — ACET slides 7.6% to $5.11, a 52-week low, 9 down days in a row
- Closed at $5.11, -7.59% vs the prior close of $5.53. Day range $5.10–$5.53, opened at $5.53.
- Volume was 326.90K shares, 1.7x its 50-day average of 197.95K.
- Price is -38.4% vs its 50-day average ($8.29) and -35.7% vs its 200-day average ($7.95).
- 52-week range $5.10–$17.44; today's close sits at 0% of that range, 70.7% below the 52-week high.
- That makes 9 straight losses.
Oct 12, 2026 — ACET dips 1.4% to $5.53, a 52-week low, 8 down days in a row
- Closed at $5.53, -1.43% vs the prior close of $5.61. Day range $5.17–$5.84, opened at $5.55.
- Volume was 145.90K shares, 0.7x its 50-day average of 197.49K.
- Price is -34.0% vs its 50-day average ($8.37) and -30.6% vs its 200-day average ($7.96).
- 52-week range $5.17–$17.44; today's close sits at 3% of that range, 68.3% below the 52-week high.
- That makes 8 straight losses.
Oct 9, 2026 — ACET dips 2.3% to $5.61, a 52-week low, 7 down days in a row
- Closed at $5.61, -2.26% vs the prior close of $5.74. Day range $5.61–$6.05, opened at $5.72.
- Volume was 189.80K shares, 1.0x its 50-day average of 194.91K.
- Price is -33.6% vs its 50-day average ($8.45) and -29.7% vs its 200-day average ($7.98).
- 52-week range $5.55–$17.44; today's close sits at 1% of that range, 67.8% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — ACET slides 7.1% to $5.74, a 52-week low on 2.6x normal volume
- Closed at $5.74, -7.12% vs the prior close of $6.18. Day range $5.55–$6.17, opened at $6.16.
- Volume was 487.60K shares, 2.6x its 50-day average of 187.00K — unusually heavy trading.
- Price is -32.6% vs its 50-day average ($8.51) and -28.1% vs its 200-day average ($7.99).
- 52-week range $5.55–$17.44; today's close sits at 2% of that range, 67.1% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — ACET dips 1.1% to $6.18, a 6-month low, 5 down days in a row
- Closed at $6.18, -1.12% vs the prior close of $6.25. Day range $6.12–$6.44, opened at $6.21.
- Volume was 214.30K shares, 1.2x its 50-day average of 183.81K.
- Price is -27.9% vs its 50-day average ($8.57) and -22.7% vs its 200-day average ($8.00).
- 52-week range $6.01–$17.44; today's close sits at 1% of that range, 64.6% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — ACET slides 3.4% to $6.25, a 6-month low, 4 down days in a row
- Closed at $6.25, -3.40% vs the prior close of $6.47. Day range $6.21–$6.55, opened at $6.52.
- Volume was 135.50K shares, 0.7x its 50-day average of 183.26K.
- Price is -27.4% vs its 50-day average ($8.61) and -21.9% vs its 200-day average ($8.00).
- 52-week range $6.01–$17.44; today's close sits at 2% of that range, 64.2% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — ACET dips 0.5% to $6.47, 3 down days in a row
- Closed at $6.47, -0.46% vs the prior close of $6.50. Day range $6.28–$6.69, opened at $6.53.
- Volume was 152.70K shares, 0.8x its 50-day average of 181.63K.
- Price is -25.1% vs its 50-day average ($8.64) and -19.2% vs its 200-day average ($8.01).
- 52-week range $6.01–$17.44; today's close sits at 4% of that range, 62.9% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ACET dips 2.1% to $6.50
- Closed at $6.50, -2.11% vs the prior close of $6.64. Day range $6.50–$6.82, opened at $6.70.
- Volume was 164.70K shares, 0.9x its 50-day average of 181.89K.
- Price is -25.0% vs its 50-day average ($8.67) and -18.9% vs its 200-day average ($8.02).
- 52-week range $6.01–$17.44; today's close sits at 4% of that range, 62.7% below the 52-week high.
ACET latest news & SEC filings
Every SEC filing by or about ACET in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$21.36M (prior year -$31.22M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.99 (prior year -$5.48) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade ACET
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 12, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.93% (largest 29.6%). That is a volatile stock.
- Liquidity: about 354.55K shares (≈$1.62M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $4.57 vs a range of $4.57–$17.04 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:16 on Dec 30, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Advisors Israel Ii Ltd Orbimed sold 32,523 shares on Apr 8, 2026.
- Latest filings: 8-K Sep 28, 2026; 8-K Sep 8, 2026; 8-K Sep 1, 2026.
- Share count: 9.36M shares outstanding (Aug 3, 2026), -88.8% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ACET market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 5.14 | 5.14 | 4.57 | 4.57 | 188.44K |
| Oct 15, 2026 | 4.90 | 5.17 | 4.88 | 5.14 | 155.10K |
| Oct 14, 2026 | 5.10 | 5.27 | 4.80 | 4.89 | 357.80K |
| Oct 13, 2026 | 5.53 | 5.53 | 5.10 | 5.11 | 326.90K |
| Oct 12, 2026 | 5.55 | 5.84 | 5.17 | 5.53 | 145.90K |
| Oct 9, 2026 | 5.72 | 6.05 | 5.61 | 5.61 | 189.80K |
| Oct 8, 2026 | 6.16 | 6.17 | 5.55 | 5.74 | 487.60K |
| Oct 7, 2026 | 6.21 | 6.44 | 6.12 | 6.18 | 214.30K |
| Oct 6, 2026 | 6.52 | 6.55 | 6.21 | 6.25 | 135.50K |
| Oct 5, 2026 | 6.53 | 6.69 | 6.28 | 6.47 | 152.70K |
| Oct 2, 2026 | 6.70 | 6.82 | 6.50 | 6.50 | 164.70K |
| Oct 1, 2026 | 7.06 | 7.17 | 6.64 | 6.64 | 148.90K |
| Sep 30, 2026 | 6.80 | 7.28 | 6.71 | 7.14 | 210.80K |
| Sep 29, 2026 | 6.41 | 7.06 | 6.37 | 6.83 | 666.60K |
| Sep 28, 2026 | 7.96 | 7.96 | 6.25 | 6.35 | 2.15M |
| Sep 25, 2026 | 8.29 | 9.11 | 8.29 | 9.02 | 638.60K |
| Sep 24, 2026 | 8.49 | 8.49 | 7.89 | 8.27 | 358.50K |
| Sep 23, 2026 | 9.12 | 9.31 | 8.42 | 8.49 | 262.50K |
| Sep 22, 2026 | 9.00 | 9.44 | 8.98 | 9.15 | 87.80K |
| Sep 21, 2026 | 9.23 | 9.24 | 8.78 | 8.93 | 49.50K |
About Adicet Bio
Adicet Bio (ACET) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 26. SEC CIK 1720580.
ACET board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey Chodakewitz | Director | Jun 23, 2026 |
| Steve Dubin | Director | Jun 23, 2026 |
| Michael Grissinger | Director | Jun 23, 2026 |
| Lloyd Klickstein | Chief Medical Officer | Aug 7, 2026 |
| Katie Peng | Director | Jun 23, 2026 |
| Chen Schor | President & CEO | Jun 23, 2026 |
| Andrew Sinclair | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Blake Aftab | Chief Scientific Officer | Jun 23, 2026 |
| Brian Nicholas Harvey | Chief Financial Officer | Mar 27, 2026 |
| Don Healey | Chief Technology Officer | Mar 27, 2026 |
| Lloyd Klickstein | Chief Medical Officer | Aug 7, 2026 |
| Julia D. Maltzman | Chief Medical Officer | Mar 27, 2026 |
| Chen Schor | President & CEO | Jun 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 8, 2026 | Advisors Israel Ii Ltd Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Advisors Israel Ii Ltd Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Advisors Israel Ii Ltd Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Advisors Israel Ii Ltd Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Advisors Llc Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Advisors Llc Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Advisors Llc Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Advisors Llc Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Israel Biofund Gp Limited Partnership Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Israel Biofund Gp Limited Partnership Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Israel Biofund Gp Limited Partnership Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Israel Biofund Gp Limited Partnership Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Capital Gp Vi Llc Orbimed | Sale | 32,523 | $6.29 |
| Apr 8, 2026 | Capital Gp Vi Llc Orbimed | Sale | 40,416 | $6.52 |
| Apr 8, 2026 | Capital Gp Vi Llc Orbimed | Sale | 32,523 | $6.29 |
ACET financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-116.80M | -16.95 | $-95.25M |
| Dec 31, 2024 | — | $-117.12M | -21.33 | $-92.38M |
| Dec 31, 2023 | — | $-142.66M | -3.31 | $-93.72M |
| Dec 31, 2022 | — | $-69.79M | -1.70 | $-44.77M |
| Dec 31, 2021 | — | $-62.00M | -2.00 | $-51.05M |
Latest balance sheet: total assets $148.17M, total liabilities $28.03M, cash $33.13M (as of Jun 30, 2026).
ACET earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $9.16 |
| May 13, 2026 | 8-K Item 2.02 (results) | $8.07 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $7.04 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $11.04 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $10.99 |
| May 6, 2025 | 8-K Item 2.02 (results) | $9.65 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $13.54 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $20.80 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
| Jan 24, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ACET
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.